Melibax Tablet contains a combination of Flupenthixol (0.5 mg) and Melitracen (10 mg), formulated to manage depressive disorders and associated anxiety symptoms. Flupenthixol is a typical antipsychotic agent belonging to the thioxanthene class, exhibiting dopamine receptor antagonism that contributes to its antipsychotic and mood-stabilizing effects. Melitracen, a tricyclic antidepressant, enhances serotonergic and noradrenergic neurotransmission by inhibiting the reuptake of serotonin and norepinephrine, thereby alleviating depressive symptoms and improving mood. The synergistic action of these two active ingredients provides effective relief from symptoms such as low mood, anxiety, fatigue, and lack of motivation. Melibax is indicated for short-term treatment of depressive states, particularly when accompanied by anxiety or agitation. It is essential to use this medication under medical supervision due to potential side effects, including extrapyramidal symptoms, anticholinergic effects, and cardiovascular disturbances. Caution is advised in patients with a history of cardiac disorders, epilepsy, or glaucoma. Dosage should be individualized based on clinical response and tolerability. Regular monitoring is recommended to assess therapeutic efficacy and detect adverse reactions promptly. Melibax Tablet should not be abruptly discontinued to avoid withdrawal symptoms or relapse.